Riskpilot← Back to searchSign inGet full accessInhalation Sciences Sweden AB
ABActiveOrg 5566656038Hälsovägen 7 6trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20045-9 employees
Revenue 2024
SEK 11M
-37% vs 2023
EBITDA margin
-45.9%
-35% vs 2023
Equity ratio
74.1%
Financial strength
Net profit 2024
SEK -5,1M
-8% vs 2023
| Revenue | SEK 11M | -37% |
| EBITDA | SEK -5,1M | -35% |
| Net profit | SEK -5,1M | -8% |
| Total assets | SEK 10,5M | -42% |
| Equity | SEK 7,8M | -40% |
| Employees | — | — |
Legal name
Inhalation Sciences Sweden AB
Org number
5566656038
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30 augusti 2004
Share capital
SEK 6 067 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling av medicinskteknisk utrustning inom diagnostik, läkemedelsutveckling och administrering samt därmed förenlig verksamhet.
Address
Hälsovägen 7 6tr
Phone
+46850884580
Email
manoush.masarrat@inhalation.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 8 022 | 5 441 | 8 949 | 10 137 | 9 422 | 12 194 | 17 504 | 11 047 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −2 333 | −4 280 | −5 852 | −11 244 | −7 896 | −8 741 | −16 571 | −12 026 | −3 756 | −5 076 |
| Depreciation & amort. | −415 | −841 | −715 | −537 | — | — | — | — | — | — |
| EBIT | −2 748 | −5 121 | −6 567 | −11 781 | −7 896 | −8 741 | −16 571 | −12 026 | −3 756 | −5 076 |
| Net financials | −106 | −244 | −180 | −102 | 3 551 | 18 618 | −38 | −99 | −988 | −71 |
| Profit before tax | −2 854 | −5 365 | −6 747 | −11 883 | −4 345 | 9 875 | −16 609 | −12 125 | −4 744 | −5 147 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 854 | −5 365 | −6 747 | −11 883 | −4 345 | 9 875 | −16 609 | −12 125 | −4 744 | −5 147 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9 191 | 10 427 | 22 981 | 19 653 | 23 569 | 18 488 | 26 112 | 12 985 | 18 168 | 10 529 |
| Equity | 2 430 | 4 127 | 15 552 | 10 806 | 5 240 | 10 475 | 19 678 | 7 553 | 12 954 | 7 807 |
| Long-term debt | 2 319 | 4 271 | 2 663 | 5 252 | 1 992 | 1 892 | 1 367 | 858 | 442 | 0 |
| Short-term debt | 4 442 | 2 029 | 0 | 3 595 | 16 337 | 6 121 | 5 067 | 4 574 | 4 772 | 2 722 |
| Total debt | 6 761 | 6 300 | 2 663 | 8 847 | 18 329 | 8 013 | 6 434 | 5 432 | 5 214 | 2 722 |
EBITDA margin
-45.9%
This company
15.8%
Market median
-391% vs market
20152024
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20152024
Return on equity
-65.9%
This company
18.4%
Market median
-458% vs market
20152024
Net profit margin
-46.6%
This company
8.1%
Market median
-675% vs market
20152024
Asset turnover
1.05×
This company
1.12×
Market median
+6% vs market
20152024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BM Chief Auditor | Chief Auditor | 2020 | — | — |
MM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Inhalation Sciences Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Manoush Masarrat Agah | Chief Executive Officer | 0 companies |
| Niklas Carl Mikael Lindecrantz | Board of Directors | 0 companies |
| Per Magnus Gerde | Board of Directors | 0 companies |
| Mårten Winge | Board of Directors | 0 companies |
| Klaus Olle Alfred Gottwald | Board of Directors | 0 companies |
| Tom Åke Gunnar Sundelin | Board of Directors | 0 companies |
| Jan Gunnar Hellqvist | Chairman | 0 companies |
| Karl Fredrik Sjövall | Chairman | 0 companies |
| Ulf Anders Ericsson | Board of Directors | 0 companies |
| Sonja Johanna Gerde | Board of Directors | 0 companies |
| Daniel Spasic | Chairman | 0 companies |